Glutowin Forte Tablet SR is a combination oral antihyperglycemic agent containing Glibenclamide 5 mg and Metformin 500 mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glibenclamide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, minimizing peak-related side effects and enhancing patient compliance through once-daily dosing. Glutowin Forte is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy with either agent is insufficient. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised due to the risk of hypoglycemia, lactic acidosis, and gastrointestinal disturbances. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Glutowin Forte Tablet SR should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.